156 related articles for article (PubMed ID: 35339379)
1. Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life.
Scope A; Bhadhuri A; Pennington B
Value Health; 2022 Sep; 25(9):1644-1653. PubMed ID: 35339379
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.
Lamsal R; Yeh EA; Pullenayegum E; Ungar WJ
Pharmacoeconomics; 2024 Feb; 42(2):199-217. PubMed ID: 37945777
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses.
Lamsal R; Yeh EA; Pullenayegum E; Ungar WJ
Pharmacoeconomics; 2024 May; ():. PubMed ID: 38819718
[TBL] [Abstract][Full Text] [Related]
4. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
Clare L; Kudlicka A; Oyebode JR; Jones RW; Bayer A; Leroi I; Kopelman M; James IA; Culverwell A; Pool J; Brand A; Henderson C; Hoare Z; Knapp M; Morgan-Trimmer S; Burns A; Corbett A; Whitaker R; Woods B
Health Technol Assess; 2019 Mar; 23(10):1-242. PubMed ID: 30879470
[TBL] [Abstract][Full Text] [Related]
5. Health state values for use in the economic evaluation of treatments for Alzheimer's disease.
Shearer J; Green C; Ritchie CW; Zajicek JP
Drugs Aging; 2012 Jan; 29(1):31-43. PubMed ID: 22191721
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
Pennington BM
Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.
Han R; François C; Toumi M
Appl Health Econ Health Policy; 2021 Jan; 19(1):29-44. PubMed ID: 32661846
[TBL] [Abstract][Full Text] [Related]
8. Growth and quality of the cost-utility literature, 1976-2001.
Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
[TBL] [Abstract][Full Text] [Related]
9. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.
Lin PJ; D'Cruz B; Leech AA; Neumann PJ; Sanon Aigbogun M; Oberdhan D; Lavelle TA
Pharmacoeconomics; 2019 Apr; 37(4):597-608. PubMed ID: 30903567
[TBL] [Abstract][Full Text] [Related]
10. The changing face of the cost-utility literature, 1990-2012.
Neumann PJ; Thorat T; Shi J; Saret CJ; Cohen JT
Value Health; 2015 Mar; 18(2):271-7. PubMed ID: 25773562
[TBL] [Abstract][Full Text] [Related]
11. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
12. The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.
Sonntag M; König HH; Konnopka A
Pharmacoeconomics; 2013 Dec; 31(12):1131-54. PubMed ID: 24293216
[TBL] [Abstract][Full Text] [Related]
13. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
Zhou T; Chen Z; Li H; Xie F
Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
[TBL] [Abstract][Full Text] [Related]
14. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.
Fryback DG; Lawrence WF
Med Decis Making; 1997; 17(3):276-84. PubMed ID: 9219187
[TBL] [Abstract][Full Text] [Related]
15. Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses.
Rankin J; Rowen D; Howe A; Cleland JGF; Whitty JA
Heart Fail Rev; 2019 Jul; 24(4):549-563. PubMed ID: 30903357
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.
Zhong Y; Lin PJ; Cohen JT; Winn AN; Neumann PJ
Value Health; 2015 Mar; 18(2):308-14. PubMed ID: 25773567
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
18. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
19. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
Neumann PJ; Fang CH; Cohen JT
Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
